| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 285,494 | 245,984 |
| Net increase in cash, cash equivalents and restricted cash | -7,313 | 215,586 |
| Cash and cash equivalents at beginning of period | 126,050 | - |
| Cash and cash equivalents at end of period | 118,737 | - |
Kymera Therapeutics, Inc. (KYMR)
Kymera Therapeutics, Inc. (KYMR)